|
Human topoisomerase II – DNA decatenation assay
Human DNA topoisomerase II alpha converts the concatenated DNA into decatenated DNA. ProFoldin offers the Human DNA topoisomerase II assays in two assay formats: Spin-column-based DNA decatenation assay and 96-well filter plate–based DNA decatenation assay. In the spin-column-based DNA decatenation assay, the decatenated DNA is separated from the concatenated DNA by a quick and easy spin-column process. The concatenated DNA stays on the column, while the decatenated DNA is eluted. The eluted DNA is quantified by fluorescence. In the 96-well filter plate–based DNA decatenation assay, the decatenated DNA is separated from the concatenated DNA by a filtration process. The decatenated DNA passed through the filter (TDD filter plate), received in a 96 well plate and quantified by fluorescence at 535 nm (excitation at 485 nm).
References:
- Merzouki A et al, Adva-27a, a Novel Podophyllotoxin Derivative Found to Be Effective against Multidrug Resistant Human Cancer Cells, Anticancer Research 32: 4423-4432 (2012).
- Frank NE et al, Comparative effects of doxorubicin and a doxorubicin analog, 13-deoxy, 5-iminodoxorubicin (GPX-150), on human topoisomerase IIβ activity and cardiac function in a chronic rabbit model. Invest New Drugs.34:693 (2016).
- Van Tine BA. et al, A phase II clinical study of 13-deoxy, 5-iminodoxorubicin (GPX-150) with metastatic and unresectable soft tissue sarcoma. Cancer Med. 8(6):2994-3003 (2019).
|
